ZA202001320B - Compounds and compositions for ire1 inhibition - Google Patents
Compounds and compositions for ire1 inhibitionInfo
- Publication number
- ZA202001320B ZA202001320B ZA2020/01320A ZA202001320A ZA202001320B ZA 202001320 B ZA202001320 B ZA 202001320B ZA 2020/01320 A ZA2020/01320 A ZA 2020/01320A ZA 202001320 A ZA202001320 A ZA 202001320A ZA 202001320 B ZA202001320 B ZA 202001320B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- compounds
- ire1
- inhibition
- ire1 inhibition
- Prior art date
Links
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553320P | 2017-09-01 | 2017-09-01 | |
| PCT/US2018/049081 WO2019046711A2 (en) | 2017-09-01 | 2018-08-31 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001320B true ZA202001320B (en) | 2023-10-25 |
Family
ID=65526075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01320A ZA202001320B (en) | 2017-09-01 | 2020-02-28 | Compounds and compositions for ire1 inhibition |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11649237B2 (enExample) |
| EP (1) | EP3675858B1 (enExample) |
| JP (1) | JP2020532589A (enExample) |
| KR (1) | KR20200066301A (enExample) |
| CN (1) | CN111526877B (enExample) |
| AU (1) | AU2018326721B2 (enExample) |
| BR (1) | BR112020004226A2 (enExample) |
| CA (1) | CA3074139A1 (enExample) |
| IL (1) | IL272845B2 (enExample) |
| MX (1) | MX2020002322A (enExample) |
| SG (1) | SG11202001609RA (enExample) |
| WO (1) | WO2019046711A2 (enExample) |
| ZA (1) | ZA202001320B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7444458B2 (ja) * | 2018-09-21 | 2024-03-06 | 学校法人福岡大学 | プリオン病治療薬 |
| US20220194945A1 (en) * | 2019-02-27 | 2022-06-23 | Optikira, LLC | Imidazolopyridine Compounds For IRE1 Inhibition |
| SG11202109194UA (en) * | 2019-02-27 | 2021-09-29 | Optikira Llc | Pyrazolopyridine compounds for ire1 inhibition |
| CA3188602A1 (en) * | 2020-08-07 | 2022-02-10 | Richard Keenan | Pyrazolopyridine compounds and methods of inhibiting ire1 using same |
| KR20230118855A (ko) * | 2020-11-13 | 2023-08-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | IRE1α 억제제 및 이의 용도 |
| WO2023131677A1 (en) * | 2022-01-07 | 2023-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compounds containing a hydroxyphenyl moiety and their use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| ES2396613T3 (es) | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| US8980899B2 (en) * | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| MX2012011504A (es) * | 2010-04-05 | 2013-01-18 | Mannkind Corp | Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa). |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| CA2886240A1 (en) * | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| WO2016004254A1 (en) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| AU2017228398A1 (en) * | 2016-03-03 | 2018-10-18 | Cornell University | Small molecule IRE1-alpha inhibitors |
| WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
-
2018
- 2018-08-31 EP EP18849820.8A patent/EP3675858B1/en active Active
- 2018-08-31 BR BR112020004226-9A patent/BR112020004226A2/pt not_active Application Discontinuation
- 2018-08-31 JP JP2020534804A patent/JP2020532589A/ja active Pending
- 2018-08-31 WO PCT/US2018/049081 patent/WO2019046711A2/en not_active Ceased
- 2018-08-31 IL IL272845A patent/IL272845B2/en unknown
- 2018-08-31 KR KR1020207009201A patent/KR20200066301A/ko not_active Ceased
- 2018-08-31 AU AU2018326721A patent/AU2018326721B2/en not_active Ceased
- 2018-08-31 CN CN201880066168.9A patent/CN111526877B/zh active Active
- 2018-08-31 SG SG11202001609RA patent/SG11202001609RA/en unknown
- 2018-08-31 US US16/642,208 patent/US11649237B2/en active Active
- 2018-08-31 CA CA3074139A patent/CA3074139A1/en active Pending
- 2018-08-31 MX MX2020002322A patent/MX2020002322A/es unknown
-
2020
- 2020-02-28 ZA ZA2020/01320A patent/ZA202001320B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3675858A4 (en) | 2021-03-17 |
| WO2019046711A2 (en) | 2019-03-07 |
| IL272845B2 (en) | 2023-12-01 |
| JP2020532589A (ja) | 2020-11-12 |
| RU2020112425A3 (enExample) | 2022-03-31 |
| IL272845B1 (en) | 2023-08-01 |
| AU2018326721B2 (en) | 2022-12-01 |
| US20200354367A1 (en) | 2020-11-12 |
| BR112020004226A2 (pt) | 2020-11-17 |
| AU2018326721A1 (en) | 2020-03-12 |
| US11649237B2 (en) | 2023-05-16 |
| CA3074139A1 (en) | 2019-03-07 |
| MX2020002322A (es) | 2020-10-05 |
| EP3675858A2 (en) | 2020-07-08 |
| EP3675858B1 (en) | 2023-04-26 |
| CN111526877A (zh) | 2020-08-11 |
| RU2020112425A (ru) | 2021-10-04 |
| CN111526877B (zh) | 2023-08-25 |
| KR20200066301A (ko) | 2020-06-09 |
| SG11202001609RA (en) | 2020-03-30 |
| WO2019046711A3 (en) | 2020-04-02 |
| IL272845A (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277125B (en) | Preparations for connecting DNA-binding domains and cleavage domains | |
| IL277006A (en) | CD73 inhibitors | |
| IL304348A (en) | cd73 inhibitors | |
| PL4234673T3 (pl) | Kompozycje | |
| GB201718801D0 (en) | Compositions and methods for inhibiting factor D | |
| IL272845A (en) | Compounds and preparations for inhibiting IRE1 | |
| GB201705971D0 (en) | Inhibitor compounds | |
| IL264446A (en) | Compounds and compositions and their use | |
| EP3349743A4 (en) | METHOD AND COMPOSITIONS FOR INHIBITING DCN1-UBC12 INTERACTION | |
| EP3280262A4 (en) | Synergistic benzoxaborole-containing anti-fungicidal composition | |
| IL274524A (en) | Preparations and methods for aquaculture | |
| ZA201801622B (en) | Composition having reduced residue | |
| PL3638277T3 (pl) | Kompozycje i sposoby hamowania beta sekretazy | |
| SG10202100751YA (en) | Compounds and compositions and uses thereof | |
| PL3568203T3 (pl) | Związki i kompozycje | |
| IL287316A (en) | compounds and preparations | |
| GB201614961D0 (en) | Compounds and compositions for use | |
| PL3589637T3 (pl) | Związki użyteczne do hamowania ror-gamma-t | |
| SG11202102727RA (en) | Immunoproteasome inhibitor formulation | |
| IL254361A0 (en) | Compounds to suppress the methyltransferase setd6 | |
| GB201707114D0 (en) | Scale inhibition composition | |
| HUE054483T2 (hu) | ROR-gamma-T gátlására alkalmas vegyületek | |
| GB201808668D0 (en) | Compounds and compositions and uses thereof | |
| HK40011187A (en) | Compounds and compositions for use | |
| GB201720145D0 (en) | Inhibitor compounds |